WESTFORD, Mass., Nov. 29, 2011 /PRNewswire/ -- Cynosure, Inc.
(NASDAQ: CYNO), a leader in laser- and light-based treatments for
minimally invasive and non-invasive aesthetic applications, today
announced that it will present at Canaccord Genuity's 6th
Annual Cardiovascular, Aesthetics & Metabolic Disorders
Conference at 1:20 p.m. (ET) on
Tuesday, December 6 in San Francisco.
The presentation by Cynosure President and CEO Michael Davin and Executive Vice President,
Treasurer and CFO Timothy Baker will
be available via live and archived audio webcast accessible through
a link on the Investor Relations section of the Company's website,
www.cynosure.com.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems
that are used by physicians and other practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and pigmented lesions, rejuvenate the skin, liquefy
and remove unwanted fat through laser lipolysis, reduce the
appearance of cellulite and treat Onychomycosis. Cynosure's
products include a broad range of laser and other light-based
energy sources, including Alexandrite, pulse dye, Q-switched,
Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure
was founded in 1991. For corporate or product information, contact
Cynosure at 800-886-2966, or visit www.cynosure.com.
Contact:
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
SOURCE Cynosure, Inc.